The milestone payment and Phase 3 initiation de-risk the elritercept program and provide a near-term capital return catalyst via the 25% distribution. Monitor for timing of payment receipt and any subsequent updates on trial enrollment or additional milestones from Takeda.
Price Chart
Executive Summary
Keros Therapeutics announced a $20 million development milestone payment from partner Takeda triggered by dosing the first patient in the Phase 3 ELRiSE MDS trial for elritercept. The company expects to distribute 25% of the net cash proceeds from this milestone to stockholders, providing a tangible near-term capital return catalyst.
Key Facts
- $20 million development milestone payment from Takeda triggered by first patient dosed in Phase 3 ELRiSE MDS trial
- Phase 3 trial (ELRiSE MDS) is a multicenter, open-label, randomized study comparing elritercept vs epoetin alfa in low-risk MDS
- Keros expects to distribute 25% of net cash proceeds from this milestone to stockholders
- Under the global license agreement (effective Jan 16, 2025), Keros received $200M upfront in Feb 2025 and is eligible for up to $1.1B+ in milestones plus tiered royalties
Financial Impact
$20 million milestone payment (~10% of $197M market cap); 25% of net proceeds to be distributed to shareholders
Risk Factors
- Clinical trial risk: Phase 3 ELRiSE MDS may fail to meet endpoints
- Dependence on Takeda partnership for development and commercialization
- No approved products; pre-revenue stage with ongoing operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000043 |
| Exhibit: exhibit99173026pr.htm | 0001664710-26-000043 |
| Document: 0001664710-26-000043-index-headers.html | 0001664710-26-000043 |
| Document: 0001664710-26-000043-index.html | 0001664710-26-000043 |
| Document: 0001664710-26-000043.txt | 0001664710-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 23d ago | 8-K | $11.31 $11.04 | ▼ −2.39% | ▼ −2.05% | $11.33 (+0.18%) |
Aug 20, 2026 6w ago | Insider Cluster | $10.95 $11.23 | ▲ +2.56% | ▲ +1.44% | $11.33 (+3.47%) |
Aug 3, 2026 8w ago | 8-K | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.33 (+10.54%) |
Aug 3, 2026 8w ago | Press Release | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.33 (+10.54%) |
Jul 30, 2026 9w ago | 8-K | $10.07 $11.15 | ▲ +10.72% | ▲ +7.21% | $11.33 (+12.51%) |
Jul 22, 2026 10w ago | 8-K | $10.14 $10.22 | ▲ +0.79% | ▲ +0.31% | $11.33 (+11.74%) |
Jun 17, 2026 15w ago | Insider Cluster | $10.65 $10.41 | ▼ −2.25% | ▼ −0.59% | $11.33 (+6.38%) |
Jun 8, 2026 16w ago | Insider Cluster | $10.07 $10.24 | ▲ +1.69% | ▼ −0.72% | $11.33 (+12.51%) |
May 14, 2026 20w ago | 8-K | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.33 (−3.09%) |
May 14, 2026 20w ago | Press Release | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.33 (−3.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access